ATHA Stock Summary and Trading Ideas (Athira Pharma | NASDAQ:ATHA)

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma trades on the NASDAQ stock market under the symbol ATHA.

As of February 28, 2025, ATHA stock price declined to $0.41 with 113,917 million shares trading.

ATHA has a market cap of $15.88 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATHA traded as high as $14.22 and as low as $.37.

The top ETF exchange traded funds that ATHA belongs to (by Net Assets): VTI, VXF, IWC.

ATHA has underperformed the market in the last year with a price return of -89.7% while the SPY ETF gained +18.8%. ATHA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.1% and -12.2%, respectively, while the SPY returned -0.4% and -2.5%, respectively.

ATHA support price is $.39 and resistance is $.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHA shares will trade within this expected range on the day.